Preliminary clinical observation of a new temperature-controlled Nitinol urethral stent system combined with medicine in the treatment of benign prostatic hyperplasia
ZHENG Dong-xiang,WANG Shu-sheng,LUO Qiao
Abstract:
Objective To evaluate the clinical value of a temperature-controlled nickel-titanium alloy urethral stent system and medicine in high-risk BPH patients, with a focus on postoperative pain, urinary function improvement, symptom relief, and safety. Methods A retrospective analysis was conducted on 4 BPH patients who underwent urethral stent implantation. Pain scores (NRS), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), quality of life (QoL), urinary white blood cell status, and postoperative complications were recorded at various time points before and after the procedure. Results The NRS score peaked briefly at 5.25±0.96 one hour postoperatively, decreased to 1.25±0.50 at 1 week, and dropped to 0 by 3 months. Qmax significantly improved from (6.93±1.05) ml/s preoperatively to (14.57±1.06) mL/s at 3 months postoperatively (P <0.01). IPSS decreased from 24.25±1.71 to 8.50±1.29 (P <0.01), and QoL scores decreased from 4.75±0.50 to 1.50±0.58 (P <0.01). The positive rate of urinary white blood cells dropped from 100% to 25%. Only two patients experienced mild complications (hematuria and urinary frequency), with no cases of stent failure, blockage, or migration observed. Conclusion Urethral stent implantation offers a minimally invasive, safe, and effective alternative for high-risk BPH patients who cannot undergo surgery, and significantly improves urinary symptoms and quality of life.
